SAN DIEGO, Calif.- UC San Diego Health announced Wednesday that it will be enrolled for a moment in a national clinical trial to expand a vaccine designed to protect against SARS-CoV-2, the new crownvirus guilty of COVID-19, until the end of the year.
Like the Modern clinical trial, which was presented last July, the National Phase III exam in AstraZeneca will recruit up to 30,000 participants at various sites across the country.
The verification arm at UC San Diego will involve approximately 1,600 participants, with special attention to underned communities, and has an expected start date of September 8.
UCSD researchers are working with the El Centro Regional Medical Center in the Imperial Valley, which has been affected by the pandemic, to create a subsite for the trial.
“The virus has struck the region’s medical and monetary well-being devastatingly,” said Dr Chris Tomaszewski, ECRMC’s medical director.”A successful vaccine trial, our purpose is more than 1,000 participants, will be to give hope as we prevent the spread of this disease in such a vulnerable community.
The UCSD trial will use a specially equipped bus to provide vaccine testing to communities in San Diego County disproportionately affected by COVID-19 and traditionally underrepresented in medical research.Two other autocellulars will serve as cellular clinics for participants who are reaching COVID- 19 study.
“The SARS-CoV-2 pandemic has had a disproportionate effect on communities of color in the United States,” dr.Susan Little, professor of medicine at UCSD Medical School and principal investigator of the UC San Diego trial.”These cars will help our curriculum provide vaccine testing opportunities to high-load communities that might be otherwise neglected.”
The trial is sponsored through the National Institutes of Health’s COVID-19 prevention network and is a component of Operation Warp Speed, a program sponsored through the US Health and Human Services Decomposer.But it’s not the first time To supply three hundred million doses of an effective VACCINE for COVID-19.until the end of the year or early 2021.
The latest candidate vaccine is a collaboration between the pharmaceutical giant AstraZeneca and the University of Oxford, founded in the United Kingdom, and is made from a weakened edition of a chimpanzee-derived, cold-causing adenovirus modified to reflect in humans.
Few others said the technique is similar to the strategy used safely in previous human vaccine trials for the prevention of Middle East respiratory syndrome, a coronavirus very similar to COVID-19.
Participants will be recruited from 81 sites. Two thirds of the participants will get the vaccine, given in two injections, at the time of injection 28 days after the first, the other third will get two injections of a salt placebo at the same time.
Participants must be 18 years of age or older and smart they must have a greater threat of SARS-CoV-2 infection due to their apartment position or non-public circumstances, such as running as first responders or in other essential industries, such as health care, maintenance, construction, grocery stores or service departments.
It is expected to last two years, with seven visits scheduled to monitor participants’ physical condition and well-being Participants will be asked to monitor COVID-19 symptoms, such as fever, shortness of breath, cough, headache and loss of taste..
– City news service
Loading…